Cadrenal Therapeutics, Inc. (CVKD)
| Market Cap | 5.36M -77.6% |
| Revenue (ttm) | n/a |
| Net Income | -11.54M |
| EPS | -4.87 |
| Shares Out | 2.87M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,904 |
| Open | 1.880 |
| Previous Close | 1.860 |
| Day's Range | 1.790 - 1.914 |
| 52-Week Range | 1.760 - 14.640 |
| Beta | 1.86 |
| Analysts | Strong Buy |
| Price Target | 14.00 (+648.66%) |
| Earnings Date | Aug 13, 2026 |
About CVKD
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatm... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CVKD stock is "Strong Buy." The 12-month stock price target is $14.0, which is an increase of 648.66% from the latest price.
News
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding Late-breaking Pha...
Cadrenal Therapeutics Quarterly report: Q2 2026
Cadrenal Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Cadrenal Therapeutics Earnings release: Q2 2026
Cadrenal Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation
Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes o...
Cadrenal Therapeutics Proxy statement: Proxy filing
Cadrenal Therapeutics filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Cadrenal Therapeutics Proxy statement: Proxy filing
Cadrenal Therapeutics filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Cadrenal Therapeutics Proxy statement: Proxy filing
Cadrenal Therapeutics filed a proxy statement on July 23, 2026, providing details for shareholder voting and corporate governance matters.
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions Company is exploring development, licensing, and c...
Cadrenal Therapeutics files to sell 2.94M shares of common stock for holders
17:12 EDT Cadrenal Therapeutics (CVKD) files to sell 2.94M shares of common stock for holders
Cadrenal Therapeutics announces clinical data from CAD-1005 study
Cadrenal Therapeutics (CVKD) announced that late-breaking clinical data from the Phase 2 study of the 12-lipoxygenase inhibitor CAD-1005 were featured in a highly anticipated late-breaking oral presen...
Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in mor...
Cadrenal Therapeutics Registration statement: Registration filing
Cadrenal Therapeutics filed a registration statement on July 13, 2026, providing details about a securities offering with the SEC.
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon the exercise in full of warrants
Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
Selection highlights the clinical value potential of Cadrenal's first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT) First-ever randomized, blinded, placebo-controlled t...
Cadrenal Therapeutics to file for FDA RPDD for tecarfarin in Kawasaki Disease
Cadrenal Therapeutics (CVKD) announced plans to submit a Rare Pediatric Disease Designation, RPDD, request to the U.S. Food and Drug Administration, FDA, for tecarfarin as a treatment for pediatric pa...
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to global pharmaceutical partners at the 2026 BIO International Convention in San Diego Kawasaki diseas...
Cadrenal Therapeutics to initiate CAD-1005 trial
Cadrenal Therapeutics (CVKD) announced that it plans to initiate a Phase 2a proof-of-concept clinical trial of its lead drug candidate, CAD-1005, being studied to prevent Acute Kidney Injury in high-r...
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussions Additional billion-dollar target- Cardiac Surgery-Associated A...
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential 12-LOX cou...
Cadrenal Therapeutics Transcript: Lytham Partners Spring 2026 Investor Conference
CAD-1005, a first-in-class 12-LOX inhibitor, targets the root cause of HIT, a rare but severe immune-mediated thrombotic disorder with high mortality and hospital costs. A pivotal registration trial is planned following positive phase II data, with potential for broader applications.
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombo...
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombo...
Cadrenal Therapeutics Quarterly report: Q1 2026
Cadrenal Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Cadrenal Therapeutics Earnings release: Q1 2026
Cadrenal Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Cadrenal Therapeutics Slides: Investor presentation
Cadrenal Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.